Non-epithelial ovarian cancer

Rachel W. Miller Assistant Professor Gynecologic Oncology University of Kentucky Markey Cancer Center

Types of Ovarian Cancer





. Epithelial Ovarian Cancer (90%)

- Serous/Papillary serous (80%)
- Mucinous (10%)
- Endometrioid (10%)
- Clear Cell
- Brenner Tumors
- *Borderline Tumors*

2. Germ Cell Tumors

- Dysgerminoma
- Yolk Sac Tumors/Endodermal sinus tumor
- Embryonal Carcinoma
- Choriocarcinoma
- Teratomas

3. Sex-cord Stromal Tumors

- Granulosa Cell Tumors
- Fibrosarcoma
- Sertoli-Leydig Tumors



Germ Cell Tumors

- 20% of all ovarian tumors
- ♦ 2-3% of ovarian malignancies
- Presentation at young age (early 20's)
- Tumor markers
 - hCG
 - le α FP
 - LDH

Evolution of Germ Cell Tumors



Ovarian Germ Cell Tumors



Germ Cell Tumors



Teratoma
Immature
Mature
Struma ovarii
Carcinoid

- Choriocarcinoma
- Embryonal carcinoma
- Polyembryoma
- Mixed GCT
- Combo GCT/Stromal
 Gonadoblastoma
 Other

Subtype	Frequency of OGCT	Benign/ Malignant	Uni- or Bi-lateral	Tumour Markers Expressed	Metastasis Route
Dysgerminoma	35-50%	Malignant	10-15% are bilateral	Serum lactic dehydrogenase and serum hCG	Lymphatic system
Endodermal sinus tumor EST	20%	Malignant	Usually unilateral	AFP (commonly), alpha1-antitrypsin (rarely)	Intraperitoneally and hematogenously
Embryonal carcinoma	Rare	Malignant	Usually unilateral	AFP and hCG	Intraperitoneally
Polyembryoma	Rare			AFP and hCG	
Choriocarcinoma	Very rare	Malignant	Usually unilateral	HCG	
Teratoma	Immature account for 20% of malignant GCT	Benign or malignant	12-15% are bilateral	Immature teratomas sometimes secrete AFP serum LDH and CA-125	
Mixed GCT	10-15%	Dependent upon the cell types present		Dependent upon the cell types present	

- Lance Armstrong
- Incidence
 - 1-2% of ovarian tumors
 - 3-5% of ovarian malignancies
 - 40% of all GCT
 - Peak incidence age 19
 - 67% stage IA
- 10-15% bilaterality
 - ♦ 20% in "normal appearing" opposite ovary





Presentation

- Solid, lobulated, and can be large
- 15% associated with mature cystic teratoma
- Associated with gonadal dysgenesis and gonadoblastoma
- High growth fraction, lymphatic spread

Tumor markers

- LDH, placental alkaline phosphatase
- Survival
 - Overall =86%
 - Stage I =90%



- Fertility-sparing surgery
 - 85% of patients are younger than 35 yo
 - Consider uterine preservation (IVF)
- Adiosensitive
- Chemotherapy
 - Combination, dose-intense regimen

- Large, round, ovoid or polygonal cells
- Nest and cords of primitive appearing germ cells
- Lymphatic space invasion is common



	Incidence	Survival
Stage IA	70%	92%
		10-year
Stage IB	10%	>90%
		5-year
Stage II, III	15%	>90%
Stage IV	5%	80%

- Presentation
 - 20% of all GCT
 - Median age 19 yo
 - Abdominal pain, large mass
 - 10-30 cm common
 - Very rapid growth, intra-abdominal and hematological spread
- Tumor marker: AFP, α_1 antitrypsin
- Synonyms
 - Yolk sac tumor
- Survival
 - Overall survival =70%
 - Stage I =90%

- Solid tumor with hemorrhage and gelatinous necrosis on cut surface
- Microscopy
 - Hyaline globules
 - Reticular Pattern
 - Schiller-Duval bodies
 - Single blood vessel surrounded by neoplastic cells





Hyaline globules $\rightarrow \alpha_1$ anti-trypsin



Schiller-Duval bodies

Teratomas

♦ Immature

- ♦ Mature
- Specialized
 - Struma ovarii
 - Carcinoid

- Presentation
 - 20% of all GCT
 - 75% in first 2 decades of life
 - 12-15% bilateral
 - 60-70% are Stage I
- *Rarely* produce tumor markers: α FP and CA-125
- Grade is determined by % immature neural tissue
- Stage IA grade $1 \rightarrow$ no adjuvant therapy
- Survival
 - Overall =63%
 - Stage I = 75%





Primitive neural elements

Grade	Scully	Norris
0	Well differentiated	All mature; rare mitoses
1	Well differentiated; rare embryonal tissue	Some immature and neuroepithelium
2	Moderate embryonal; atypia and mitoses	Immature neuroepithelium $\leq 3 \text{ lpf}$
3	Large embryonal; atypia and mitoses	Immature neuroepithelium in \geq 4 lpf



Grade	Number	Tumor Deaths
1	22	4 (18%)
2	24	9 (37%)
3	10	7 (70%)

- ♦ 5-25% of all ovarian tumors
 - 10-20% bilateral

Most common ovarian tumor of young women

- Sonography
 - Complex, cystic and solid
 - Fat/fluid or hair/fluid level, calcifications
 - High MI score
- ♦ 1-2% with malignant degeneration
 - Rokitansky's protuberance
 - Squamous cell cancers possible









Sebaceous glands



Intestinal gland formation

Specialized Teratomas

- Struma ovarii
 - 2-3% of all teratomas
 - 25-35% have symptoms of hyperthyroidism
 - Usually benign, but may undergo malignant transformation
- Carcinoid tumors
 - Associated with GI or respiratory epithelium
 - Primary ovarian tumors are rare (N=50)
 - Often older postmenopausal women
 - ♦ 1/3 have carcinoid syndrome from serotonin
 - Symptoms resolve with excision
 - 5-hydroxyindoleacetic acid in urine

Struma Ovarii

- Follicles contain vividly eosinophilic, acellular colloid
- Variation in follicular size is typical
- Can have rich vascularity



Ovarian Carcinoid

- Insular pattern
- Round uniform cells
- Fibroconnective tissue background
- 80% with neurosecretory granules



Choriocarcinoma

- Presentation
 - Uncommon, aggressive tumor
 - Often part of mixed GCT
 - Consider met from gestational chorioCA
 - Mean age 20 yo, children common
 - Half of premenarchal \rightarrow precocious puberty
- Tumor marker
 - ♦ hCG

Choriocarcinoma

Cytotrophoblast

Cytotrophoblast

Smaller cells

- Smaller nuclei
- Syncitiotrophoblast
 - Larger cells
 - Eosinophilic cytoplasm
 - Bizarre nuclei

Hemorrhage



Syncitiotrophoblast

Embryonal Carcinoma



- ♦ Mean age < 30 yo</p>
- Only 4% of GCT and often part of mixed tumor
- 60% Stage IA
- Poorly differentiated germ cell tumor
- Aggressive, intra-abdominal spread and mets common
- Tumor markers: hCG, α FP
- Survival
 - Overall =40%
 - Stage I =75%

Embryonal Carcinoma

- Large, primitive cells
- Papillary or gland-like formation, occasional
- Sheets and ribbons



Polyembryona

- Best classified as a mixed tumor
 - Never found in pure form
 - Fewer than 50 cases
 - All under age 40
- Resembles embryonal carcinoma
 - Embryo days 13-15
- Treated like other mixed GCT
- Tumor markers: hCG, α FP

Mixed GCT Embryonal and Choriocarcinoma



Gonadoblastoma

Combined Germ Cell / Sex Cord Stromal Tumor

Presentation

- Age 1-38
- Small tumors
- ♦ Phenotypic ♀ with virilization
 - 90% have Y chromosome
 - 22% from streak gonads
- Bilaterality 30-50%
- Check chromosomes for dysgenic gonads
 - BSO if Y present
 - If testicular feminization syndrome, await puberty before BSO

Gonadoblastoma

- Large germ cells, clear cytoplasm
- Nests of primordial germ cells surrounded by specialized stromal cells
- Associated sex cord stromal cells



Gonadoblastoma

Tumor Markers Germ Cell Tumors

Histology	AFP	hCG	LDH	PLAP	CA-125
Dysgerminoma	-	+	+	+	+
Endodermal sinus tumor	+	-	+	-	+
Immature teratoma	+	-	-	-	+
Embryonal CA	+	+	-	+	-
ChorioCA	-	+	-	+	-

Germ Cell Tumors Treatment



- Importance of staging in early disease
- Fertility-sparing surgery often required
- Can preserve uterus for future IVF, even if BSO
- Debulking improves outcome

Chemotherapy Germ Cell Tumors

♦ BEP

- Bleomycin 20 U/m² weekly x 9
- Etoposide 100 mg/m² days 1-5 q 3 weeks x 3
- Cisplatin 20 mg/m² days 1-5 q 3 weeks x 3

• VAC

- Vincristine 105 mg/m² weekly x 12
- Act D 0.5 mg days 1-5 q 4 weeks
- Cytoxan 5-7 mg/kg days 1-5 q 4 weeks

♦ VBP

- Vinblastine 12 mg/m² q 3 weeks x 4
- Bleomycin 20 U/m² weeks x 7, 8 on week 10
- Cisplatin 20 mg/m² days 1-5 q 3 weeks x 3

Sex-cord Stromal Tumors

- Fibroma
- Granulosa cell tumors
 Inhibin, CA-125
- Sertoli-Leydig tumors
 CA-125, α FP, sTest
- Steroid cell tumors
 - sTest (50-75% virilized)
- ♦ Gynandroblastoma
 ♦ and ♂ components

Fibroma



- Presentation
 - Adult (95%) and juvenile types
 - Solid and/or cystic- variable
 - Estrogen, occasional androgen
 - 80% palpable on examination
 - Hemoperitoneum in 15%
 - 80-90% Stage I
 - Low grade, late relapse
- Estrogen excess and the endometrium
 - 25% proliferative
 - 55% hyperplastic
 - ♦ 13% adenocarcinoma

Granulosa Cell Tumor Treatment

Juvenile

• High cure rate

- Adult
 - Resection
 - Chemotherapy
 - ♦ BEP
 - Carboplatin and Taxol
 - GnRH analogs









Call-Exner bodies

Sertoli-Leydig Tumors

Benign

- ♦ Sertoli cell tumors \rightarrow no hormones
- ♦ Leydig tumors→ testosterone
- Potentially Malignant
 - Sertoli-Leydig tumors
 - Arrhenoblastoma, androblastoma
 - Grade 3
 - 44% five-year survival

Grade	% Cancer
1	0
2	10
3	60

Sertoli-Leydig Tumor



Well-differentiated tubules

Treatment Summary

Germ Cell and Stromal Tumors of the Ovary

Dysgerminoma	USO staging if possible	BEP x 3 cycles if stage II-IV
Endodermal sinus tumor	Debulk but preserve fertility	BEP x 3-4 cycles
Embryonal carcinoma	As above	BEP x 3-4 cycles
Malignant teratoma	As above	BEP or VAC x 3-4 cycles
Granulosa cell tumor	USO if young o/w TAH/BSO	BEP x 3-4 cycles GnRH agonists for advanced ds.
Sertoli-leydig cell	As above	BEP or VAC x 3-4 cycles

Summary

- 1. Common in young women
- 2. Tumor markers
- 3. Treatment
 - Fertility-sparing surgery
 - Chemosensitive \rightarrow BEP for 3-6 cycles
 - Radiosensitive
- 4. No adjuvant chemo for:
 - Stage I pure dysgerminoma
 - Stage IA grade 1 immature teratoma